What we do

Catalonia.health and IDIAP Jordi Gol have organized the Primary Care Edition conference, which has connected six real clinical challenges of primary care with the companies that propose solutions

Helsinki, June 2026 – Our Project Coordinator, Roser Alba, participated this week in the third study visit of the European project RISEMED4EU (Regional Innovation for Smart Ecosystems in Health and Medicine in the EU), held in Helsinki with representatives of the eight partner regions of the consortium: Limburg (Netherlands), Helsinki-Uusimaa (Finland), Saxony-Anhalt (Germany), Western Slovenia, North-East Romania, Emilia-Romagna (Italy), Bosnia and Herzegovina and Catalonia.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has presented updated positive clinical data from two clinical trials with its selective LSD1 inhibitor, iadademstat, in acute myeloid leukemia (AML), at the 2026 Annual Congress of the European Association of Hematology (EHA), held on June 11.

The Catalan biotechnology company AbilityPharma and the Vall d'Hebron Institut de Recerca (VHIR), both members of Catalonia.health, participate prominently in the European PHOENIX project, funded with 8.5 million euros by the European Union through Horizon Europe's Cancer Mission program.

The biotechnology company Gate2Brain, a member of Catalonia.health, has announced a strategic alliance with Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited, which includes an investment of 7 million euros and a 30.4% stake in the company. This is the largest investment raised by Gate2Brain since its foundation in 2020 and consolidates the growth achieved in less than six years of activity.

Catalonia.health's IMPULS program hosted a new Lessons Learned session focused on the real path to B Corp certification, with the participation of four leading companies in the health sector.

Biotech company CONNECTA Therapeutics, member of Catalonia.health, has announced the start of a Phase IIa clinical trial with its most advanced program, CTH120, in adult males with fragile X syndrome (FSX). The milestone comes after the positive safety results obtained in Phase I and represents a key step in the company's evolution.

Biopharmaceutical company Ona Therapeutics, member of Catalonia.health, has announced the closing of an oversubscribed $86.6 million Series B funding round aimed at advancing the clinical development of its first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers resistant to current treatments.

The event brought together all the members of the consortium and highlighted the collaborative work between technology, clinic and ecosystem

Ambit Iberia, member of Catalonia.health, organized last June 3 in Barcelona a new edition of Ambit Meets: Tech Trends & Compliance in Life Science, its annual event aimed at professionals in the Life Sciences sector to share experiences, analyze trends and debate the challenges that will mark the future of the industry.

The pharmaceutical company Medichem, a member of Catalonia.health, has been awarded the Second COASHIQ Sustainability Award for its "Waste, Water and Climate Change Management Programs" project, during the 122nd COASHIQ Technical Assembly and Conference, held on May 19 and 20 in Valencia.

The report prepared by Catalonia.health and EY analyzes the state of investment, the global trends and the challenges of the Catalan health sector in an increasingly competitive geopolitical context

Last May 9, on the occasion of Europe Day, Catalonia.health was present at the institutional event commemorating the 40th anniversary of the accession of Catalonia and Spain to the European Union. Representing the presidency of the association and its associates, the vice-president of Catalonia.health, Pau Turón, attended.

Asabys Partners, a venture capital firm specialized in life sciences and a member of Catalonia.health, has been selected in the Innvierte Deep Start call, promoted by the Center for Technological Development and Innovation (CDTI) in collaboration with the European Investment Fund (FEI), within the framework of Spain's National Deep Tech Strategy 2026-2030.

Integra Therapeutics, member of Catalonia.health, has presented new preclinical results of its FiCAT platform at the American Society for Gene and Cell Therapy (ASGCT) congress.

The Connection Day 2026, organized by Catalonia.health, has celebrated its fourth edition with a notable success in terms of participation and content. The event, held on May 6 at the World Trade Center in Barcelona, was consolidated as the reference B2B meeting point for the health sector in Catalonia, where more than 250 professionals from the entire value chain gathered: startups, companies, investors, hospitals, research centers and institutions.

Majesty King Felipe VI has inaugurated the CaixaResearch Institute, the first center dedicated entirely to the study of immunology in Spain and Portugal, and one of the pioneers in Europe. The new institute, promoted by the "la Caixa" Foundation and a Catalonia.health member, represents an investment of €100 million and strengthens Catalonia's biomedical research ecosystem.

Catalan company INBRAIN Neuroelectronics, a member of Catalonia.health, has announced the completion of patient enrolment in its first-in-human study of graphene-based neural interfaces for brain decoding and mapping.

Catalan biotech company Aniling, a member of Catalonia.health, has announced a strategic collaboration with Illumina to advance unified genomic and epigenetic assays in oncology.

Catalan biotech company Sequentia Biotech, a member of Catalonia.health, has announced the achievement of CE-IVD marking under the new European IVDR regulation for its MICK Clinical™ solution, designed for gastrointestinal pathogen diagnostics.